ArticleMetabolomics : Official journal of the Metabolomic Society2026
Urinary metabolomics profile in children with ureteropelvic junction obstruction.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFetal hydronephrosis (HN) is detected in about 0.25-1% of fetuses, where ureteropelvic junction obstruction (UPJO) is the most commonly found congenital urinary tract anomaly, remaining the leading cause of kidney failure in infants and children. Since it is a spectral disease, UPJO represents a particularly challenging management. Severe UPJO must be treated surgically to avoid impairment of renal function, but children with non-obstructive hydronephrosis can be treated conservatively. There has been controversy regarding the indication for surgical intervention in asymptomatic patients.
objectivesThis pilot study aimed at investigating urine samples from children with UPJO using gas- and high-performance liquid-chromatography coupled to mass spectrometry (GC- and HPLC-MS) via untargeted metabolomics to prospect discriminatory metabolites indicative of hydronephrosis spectral progression that may contribute to optimize clinical decision-making.
methodsThirty-seven patients, whose clinical characteristics were recorded upon visits, had urinary samples collected, processed and analyzed by both GC- and HPLC-MS analytical platforms. Three distinct age-matched groups (2-12 years old) were inspected: 10 children with obstructive HN (OHN) established at initial imaging diagnosis, 15 asymptomatic children with non-obstructive HN (NOHN), and 12 children without any urinary tract problems as control group (CTR). Univariate analysis (including distribution checking and goodness-of-fit testing using ANOVA, Tukey test, and Benjamini-Hochberg procedure for FDR estimation) and multivariate analysis (PLS-DA, using cross-validation and permutation testing) were applied to the metabolomics data. Exploratory ROC curve analyses were performed using combinations of PLS-DA ranked features with VIP > 1 to assess their discriminatory performance.
resultsMetabolomics profiling revealed distinct expression patterns upon selected group comparisons. The inspection of discriminatory metabolites across the different study groups allowed a clear visualization of the disease progression at the molecular level. Moreover, the discrimination of asymptomatic patients (NOHN group) from those requiring surgical intervention (OHN group) is of upmost relevance and could also be delineated here. All univariate and multivariate methods applied to both GC- and HPLC-MS data exhibited good statistical performance (adjusted p-values < 0.05, 0.04 < q-values < 0.1, and 0.662 < AUC < 0.882 for univariate analysis; p-value < 0.03, 3 < F < 11.4, 0.984 < R
conclusionDespite the limited size and age spanning of the cohort evaluated here, the statistical quality of the present study, that certified 17 metabolites by both univariate and multivariate methods among 94 discriminant metabolites, deriving from NOHN, OHN, and CTR group comparisons, may contribute to pave the way into searching valuable biomarkers for the obstructive HN setting up and progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.